Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E.

Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2. No abstract available.

PMID:
27911126
2.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
3.

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU.

Acta Oncol. 2013 Nov;52(8):1786-8. doi: 10.3109/0284186X.2013.786839. Epub 2013 Apr 23. No abstract available.

PMID:
23607756
4.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

5.

Place des anti-PD1 dans la prise en charge des mélanomes cutanés.

Mateus C, Libenciuc C, Robert C.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S4-S11. doi: 10.1016/S0007-4551(16)30140-0. Review. French.

PMID:
27494973
6.

Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.

Amode R, Baroudjian B, Kowal A, Jebali M, Allayous C, Bagot M, Madjlessi N, Roux J, Viguier M, Basset Seguin N, Porcher R, Pagès C, Lebbé C.

Melanoma Res. 2017 Apr;27(2):110-115. doi: 10.1097/CMR.0000000000000313.

PMID:
27926587
7.

Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?

Bender C, Enk A, Gutzmer R, Hassel JC.

Cancer Med. 2017 Jul;6(7):1581-1586. doi: 10.1002/cam4.887. Epub 2017 Jun 21.

8.

PD-1 Blockers.

Wolchok JD.

Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.

9.

A rapid response to pembrolizumab in a patient with metastatic melanoma.

Bayo Calero J, Aviñó Tarazona V.

Immunotherapy. 2017 Mar;9(3):225-228. doi: 10.2217/imt-2016-0136.

PMID:
28231724
10.

Uveal melanoma.

Spagnolo F, Caltabiano G, Queirolo P.

Cancer Treat Rev. 2012 Aug;38(5):549-53. doi: 10.1016/j.ctrv.2012.01.002. Epub 2012 Jan 24. Review.

PMID:
22270078
11.

Uveal melanoma: evidence for adjuvant therapy.

Choudhary MM, Triozzi PL, Singh AD.

Int Ophthalmol Clin. 2015 Winter;55(1):45-51. doi: 10.1097/IIO.0000000000000057. Review. No abstract available.

PMID:
25436492
12.

Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.

Ribeiro Gomes J, Schmerling RA, Haddad CK, Racy DJ, Ferrigno R, Gil E, Zanuncio P, Buzaid AC.

J Immunother. 2016 Nov/Dec;39(9):367-372.

PMID:
27741091
13.

Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.

Niederkorn A, Wackernagel W, Artl M, Schwantzer G, Aigner B, Richtig E.

Acta Ophthalmol. 2014 Dec;92(8):e696-7. doi: 10.1111/aos.12432. Epub 2014 Apr 28. No abstract available.

14.

Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.

Harvey NT, Millward M, Macgregor K, Bucat RP, Wood BA.

Am J Dermatopathol. 2016 Dec;38(12):e159-e162.

PMID:
27870733
15.

Programmed death protein 1 inhibitors making inroads in multiple cancers.

Brower V.

J Natl Cancer Inst. 2015 May 9;107(5). pii: djv141. doi: 10.1093/jnci/djv141. Print 2015 May. No abstract available.

PMID:
25957444
16.

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.

Maul LV, Weichenthal M, Kähler KC, Hauschild A.

J Immunother. 2016 May;39(4):188-90. doi: 10.1097/CJI.0000000000000118.

PMID:
27023060
17.

[Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].

Robert C, Mateus C.

Bull Acad Natl Med. 2014 Feb;198(2):297-308. French.

PMID:
26263705
18.

Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma.

Thoreau B, Gouaillier-Vulcain F, Machet L, Mateus C, Robert C, Ferreira-Maldent N, Maillot F, Lioger B.

Acta Derm Venereol. 2017 Mar 10;97(3):408-409. doi: 10.2340/00015555-2504. No abstract available.

19.

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.

Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M.

Expert Rev Anticancer Ther. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30. Review.

PMID:
26313415
20.

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J.

Br J Cancer. 2016 Feb 2;114(3):256-61. doi: 10.1038/bjc.2015.467. Epub 2016 Jan 21.

Supplemental Content

Support Center